Catalyst
Slingshot members are tracking this event:
Seattle Genetics Expects to Complete Enrollment in the Phase 3 ECHELON-2 Trial in Frontline Mature T-cell Lymphoma (MTCL) During 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 08, 2016
Occurred Source:
http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2220520
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Echelon-2 Trial, Phase 3, T-cell Lymphoma, Adcetris, Frontline Mtcl
